Koers WuXi Biologics (Cayman) Inc. Hong Kong S.E.
Aandelen
2269
KYG970081090
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 18,18 mld. 2,51 mld. 19,61 mld. 2,33 mld. | Omzet 2025 * | 21,76 mld. 3 mld. 23,47 mld. 2,79 mld. | Marktkapitalisatie | 53,84 mld. 7,44 mld. 58,07 mld. 6,91 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 3,89 mld. 538 mln. 4,2 mld. 500 mln. | Nettowinst (verlies) 2025 * | 4,93 mld. 680 mln. 5,31 mld. 632 mln. | EV/omzet 2024 * | 2,57 x |
Nettoliquiditeiten 2024 * | 7,11 mld. 982 mln. 7,67 mld. 913 mln. | Nettoliquiditeiten 2025 * | 8,06 mld. 1,11 mld. 8,7 mld. 1,04 mld. | EV/omzet 2025 * | 2,1 x |
K/w-verhouding 2024 * |
14,3
x | K/w-verhouding 2025 * |
11,2
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 85,47% |
Recentste transcriptie over WuXi Biologics (Cayman) Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Zhi Sheng Chen
CEO | Chief Executive Officer | 52 | 01-06-11 |
Ming Tu
DFI | Director of Finance/CFO | 54 | 23-08-21 |
Gu Jijie
CTO | Chief Tech/Sci/R&D Officer | 57 | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jackson Tai
BRD | Director/Board Member | 73 | 06-05-23 |
William Keller
BRD | Director/Board Member | 75 | 17-05-17 |
Ge Li
CHM | Chairman | 56 | 01-05-10 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,96% | 105 mld. | |
-1,43% | 104 mld. | |
+4,40% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-4,36% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+38,61% | 12,63 mld. | |
+313,59% | 8,49 mld. |